» Articles » PMID: 20497311

Hepatitis C Testing Practices and Prevalence in a High-risk Urban Ambulatory Care Setting

Overview
Journal J Viral Hepat
Specialty Gastroenterology
Date 2010 May 26
PMID 20497311
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Approximately 3.2 million persons are chronically infected with the hepatitis C virus (HCV) in the U.S.; most are not aware of their infection. Our objectives were to examine HCV testing practices to determine which patient characteristics are associated with HCV testing and positivity, and to estimate the prevalence of HCV infection in a high-risk urban population. The study subjects were all patients included in the baseline phase of the Hepatitis C Assessment and Testing Project (HepCAT), a serial cross-sectional study of HCV screening strategies. We examined all patients with a clinic visit to Montefiore Medical Center from 1/1/08 to 2/29/08. Demographic information, laboratory data and ICD-9 diagnostic codes from 3/1/97-2/29/08 were extracted from the electronic medical record. Risk factors for HCV were defined based on birth date, ICD-9 codes and laboratory data. The prevalence of HCV infection was estimated assuming that untested subjects would test positive at the same rate as tested subjects, based on risk-factors. Of 9579 subjects examined, 3803 (39.7%) had been tested for HCV and 438 (11.5%) were positive. The overall prevalence of HCV infection was estimated to be 7.7%. Risk factors associated with being tested and anti-HCV positivity included: born in the high-prevalence birth-cohort (1945-64), substance abuse, HIV infection, alcohol abuse, diagnosis of cirrhosis, end-stage renal disease, and alanine transaminase elevation. In a high-risk urban population, a significant proportion of patients were tested for HCV and the prevalence of HCV infection was high. Physicians appear to use a risk-based screening strategy to identify HCV infection.

Citing Articles

Hepatitis C antibody screening and determinants of initial and duplicate screening in the baby boomer patients of six urban primary care clinics.

Coppock D, Chou E, Gracely E, Gross R, Heun-Lee D PLoS One. 2020; 15(7):e0235778.

PMID: 32645083 PMC: 7347094. DOI: 10.1371/journal.pone.0235778.


Evolving trends in the prevalence of hepatitis C virus antibody positivity among HIV-infected men in a community-based primary care setting.

Chen Y, Thio C, Kamangar F, Cox A, Wiberg K J Viral Hepat. 2020; 27(11):1202-1213.

PMID: 32579777 PMC: 7544680. DOI: 10.1111/jvh.13354.


Leveraging the electronic health record to eliminate hepatitis C: Screening in a large integrated healthcare system.

Geboy A, Nichols W, Fernandez S, Desale S, Basch P, Fishbein D PLoS One. 2019; 14(5):e0216459.

PMID: 31120906 PMC: 6532960. DOI: 10.1371/journal.pone.0216459.


Hepatitis C Screening in Commercially Insured U.S. Birth-cohort Patients: Factors Associated with Testing and Effect of an EMR-based Screening Alert.

Yeboah-Korang A, Beig M, Khan M, Goldstein J, Macapinlac D, Maurer D J Transl Int Med. 2018; 6(2):82-89.

PMID: 29984203 PMC: 6032190. DOI: 10.2478/jtim-2018-0012.


Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy.

Willis S, Cole S, Westreich D, Edmonds A, Hurt C, Albrecht S AIDS. 2018; 32(5):653-661.

PMID: 29334550 PMC: 6024258. DOI: 10.1097/QAD.0000000000001745.


References
1.
Galmiche J . French consensus conference on hepatitis C: screening and treatment. Gut. 1998; 42(6):892-8. PMC: 1727138. DOI: 10.1136/gut.42.6.892. View

2.
Dinwiddie S, Shicker L, Newman T . Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry. 2002; 160(1):172-4. DOI: 10.1176/appi.ajp.160.1.172. View

3.
Himelhoch S, McCarthy J, Ganoczy D, Medoff D, Kilbourne A, Goldberg R . Understanding associations between serious mental illness and hepatitis C virus among veterans: a national multivariate analysis. Psychosomatics. 2009; 50(1):30-7. PMC: 3774160. DOI: 10.1176/appi.psy.50.1.30. View

4.
Volk M, Tocco R, Saini S, Lok A . Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009; 50(6):1750-5. DOI: 10.1002/hep.23220. View

5.
Manns M, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286):958-65. DOI: 10.1016/s0140-6736(01)06102-5. View